Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06847399

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Led by Johns Hopkins University · Updated on 2025-09-22

105

Participants Needed

1

Research Sites

115 weeks

Total Duration

On this page

Sponsors

J

Johns Hopkins University

Lead Sponsor

E

Eli Lilly and Company

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate. All participants will receive guided self-help cognitive behavioral therapy.

CONDITIONS

Official Title

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have a body mass index (BMI) of 30 kg/m2 or higher, or 27 kg/m2 or higher with at least one obesity-related health condition
  • Have at least one self-reported unsuccessful attempt to lose weight through diet
  • Meet the Diagnostic and Statistical Manual (DSM)-5 criteria for moderate or greater binge eating disorder with 4 or more episodes per week
  • Be 18 years of age or older
  • Participants assigned female at birth who are not of childbearing potential may participate, including those infertile due to surgery or congenital anomaly, postmenopausal, or 55 years or older
  • Female participants of childbearing potential must test negative for pregnancy at the start and agree to use two forms of contraception if sexually active
  • Understand and agree to follow study procedures and give written informed consent
  • Be willing and able to learn self-injection or receive assistance, take oral capsules daily, and comply with study requirements
Not Eligible

You will not qualify if you...

  • Current diagnosis of bulimia nervosa or anorexia nervosa
  • Have type 1 or type 2 diabetes mellitus, history of ketoacidosis, or hyperosmolar state
  • Laboratory evidence of diabetes during screening (HbA1c ≥6.5% or fasting glucose >126 mg/dL)
  • Weight change greater than 5 kg in the past 3 months
  • Prior or planned surgical treatment for obesity within specified timeframes
  • Prior or planned endoscopic or device-based therapy for obesity within 6 months
  • Family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2
  • Known serious allergy to study drugs or their ingredients
  • Severe gastrointestinal disease or significant kidney problems
  • Uncontrolled medical conditions or contraindications to study drugs
  • Personal or family history of cardiovascular disease increasing risk with stimulant medications
  • History of substance abuse within 5 years or lifetime psychostimulant abuse
  • Glaucoma, pancreatitis, certain endocrine or genetic obesity disorders
  • Current diagnosis of attention-deficit/hyperactivity disorder
  • Recent or unstable major depressive disorder or severe psychiatric disorders
  • High Patient Health Questionnaire-9 (PHQ-9) score or history of suicide attempts or risk
  • Recent use of monoamine oxidase inhibitors
  • Uncontrolled high blood pressure
  • Cardiovascular events within 3 months prior to study
  • History of active or untreated cancers within 5 years
  • History of seizures, neurological diseases, or serious heart conditions
  • Any other condition that may prevent following the study protocol
  • Receiving concurrent treatment for eating or weight disorders
  • Use of psychostimulants within the past 6 months
  • Use of weight loss medications within 3 months prior
  • Current participation in incompatible clinical studies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Johns Hopkins University

Baltimore, Maryland, United States, 21146

Actively Recruiting

Loading map...

Research Team

A

Abigail Bisson, BS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here